Futuros bisomilares: pros y contras
enero 20, 2016
Note: This story was originally published in the January 2016 issue of BioSupply Trends Quarterly. It can be read in its original format here. By
Menú
Note: This story was originally published in the January 2016 issue of BioSupply Trends Quarterly. It can be read in its original format here. By
The recent outbreak of Ebola virus has caused great concern among many people. We read stories about isolation, experimental therapies and many deaths. It is
FDA Approves Baxter’s RIXUBIS as First Recombinant Factor IX Treatment for Routine Prophylaxis of Hemophilia BApproval brings patients first new rFIX treatment option in more
FOR IMMEDIATE RELEASEMedia Contacts:Deborah Spak, (847) 948-2349 Marie Kennedy, (805) 372-3543Investor Contacts:Mary Kay Ladone, (847) 948-3371 Clare Trachtman, (847) 948-3085BAXTER INITIATES PHASE III TRIAL OF
Español de Puerto Rico 
English